US-based neuro42 Bags Investment to Bring Enhanced Neurosurgical Technology

Serial investor Karna D Shinde's investment propels advancements in portable US FDA-cleared MRI and robotics for enhanced neuroimaging and precision interventions.

US-based medtech startup, neuro42 has received an undisclosed amount of investment from serial investor, Karna D Shinde, in his third round of investment in the startup.

Founded in 2020, by Amit Vohra, Michael Bartholomew, and Nikhil Sadhwani, neuro42, Inc is a medtech startup advancing futuristic technologies for screening, diagnosis, and targeted treatment of neurological conditions. The startup is developing and commercializing a portable MRI, robotic, and AI platform, backed by over 30 patents, for point-of-care imaging and interventions under live image guidance. 

Underlining the significance of this investment, Karna D Shinde, investor and strategic advisor, said, "The diagnostic and interventional capabilities of neuro42’s MRI have the potential to transform the way challenging brain tumor cases are approached and treated.”

neuro42 Offerings

Recently, neuro42 received clearance of its diagnostic MRI product by the US FDA. This regulatory approval, received in February 2024, laid the groundwork for the anticipated commercial launch of its advanced diagnostic MRI machine later this year.

Sharing insights, Abhita Batra, founder and chief strategy officer, neuro42, said, "We are thrilled to announce the FDA clearance of our bedside MRI product. Our team has been focused on making a difference in patient care, and now we can finally arm healthcare providers with a valuable tool to improve accessibility to neuroimaging."

neuro42's MRI technology, tailored for brain imaging and interventions, garnered interest from healthcare facilities in states including Telangana, Maharashtra, and Karnataka.

Latest Technological Advancements in Healthcare Space

Recently, US health insurance giant Kaiser Permanente is reportedly in advanced stages of negotiations to invest in Silicon Valley-based healthcare technology company Innovaccer. The investment, estimated between $200 and $250 million, encompasses both primary and secondary funding. 

Additionally, US-based Avive Solutions, a portable defibrillator manufacturer, secured $56.5 million in growth equity financing. This move comes in response to the critical need to improve survival rates for individuals experiencing cardiac emergencies.

To expedite response times for sudden cardiac arrest (SCA) incidents, Avive Solutions strategically deployed a network of connected defibrillators across various cities in the United States. 

The funding infusion is expected to accelerate the company's efforts in deploying connected defibrillators across various sectors, including corporations, government agencies, fitness chains, universities, and school districts. The funding round was spearheaded by Questa Capital, Laerdal Million Lives Fund, and Catalyst Health Ventures.